These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8823963)

  • 1. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada.
    De Wals P; Dionne M; Douville-Fradet M; Boulianne N; Drapeau J; De Serres G
    Bull World Health Organ; 1996; 74(4):407-11. PubMed ID: 8823963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing epidemiology of meningococcal invasive disease in the Czech republic caused by new clone Neisseria meningitidis C:2a:P1.2(P1.5), ET-15/37.
    Krizova P; Musilek M
    Cent Eur J Public Health; 1995 Nov; 3(4):189-94. PubMed ID: 8903519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies].
    Aplogan A; Batchassi E; Yakoua Y; Croisier A; Aleki A; Schlumberger M; Molina S; Sidatt M; Kaninda AV
    Sante; 1997; 7(6):384-90. PubMed ID: 9503496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec.
    De Wals P; De Serres G; Niyonsenga T
    JAMA; 2001 Jan; 285(2):177-81. PubMed ID: 11176810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec.
    De Wals P; Deceuninck G; De Serres G; Boivin JF; Duval B; Remis R; Massé R
    Clin Infect Dis; 2005 Apr; 40(8):1116-22. PubMed ID: 15791510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evolution of meningococcal infection among infant population in the autonomous community of Valencia (1996-2000). Effectiveness of A+C meningococcal vaccination].
    Goicoechea Sáez M; Fullana Montoro AM; Momparler Carrasco P; Redondo Gallego MJ; Brines Solanes J; Bueno Cañigral FJ
    Rev Esp Salud Publica; 2003; 77(1):125-42. PubMed ID: 12696392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A.
    Erwa HH; Haseeb MA; Idris AA; Lapeyssonnie L; Sanborn WR; Sippel JE
    Bull World Health Organ; 1973; 49(3):301-5. PubMed ID: 4211056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
    Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA;
    Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria.
    Wahdan MH; Sallam SA; Hassan MN; Abdel Gawad A; Rakha AS; Sippel JE; Hablas R; Sanborn WR; Kassem NM; Riad SM; Cvjetanović B
    Bull World Health Organ; 1977; 55(6):645-51. PubMed ID: 413639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bacterial meningitis caused by Neisseria meningitidis. Prophylactic measures].
    Magdzik W
    Przegl Epidemiol; 2004; 58(2):241-51. PubMed ID: 15521103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of 2 vaccination strategies on developments during the epidemic of meningococcal A meningitis in N'Djamena (Chad) in 1988].
    Spiegel A; Greindl Y; Lippeveld T; Decam C; Granga D; Nahor N; Bordonado JL; Sperber G; Yankalbe M; Baudon D
    Bull World Health Organ; 1993; 71(3-4):311-5. PubMed ID: 8324849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
    Noronha CP; Struchiner CJ; Halloran ME
    Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].
    da Silva A; Parent du Châtelet I; Beckr Gaye A; Dompnier JP; Seck I
    Sante; 2003; 13(4):215-23. PubMed ID: 15047438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tetravalent anti-meningococcal vaccine: serologic and clinical evaluation].
    Vescia N; Mastroeni I; Pompa MG; Signorelli C; Fara GM
    Ann Ig; 1989; 1(6):1293-8. PubMed ID: 2484465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Observation on the epidemiologic efficacy for 9 years on epidemic meningococcal polysaccharide vaccine of group A by district immunization method].
    Ma Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 1991 Apr; 12(2):69-71. PubMed ID: 2065343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease.
    De Wals P; Nguyen VH; Erickson LJ; Guay M; Drapeau J; St-Laurent J
    Vaccine; 2004 Mar; 22(9-10):1233-40. PubMed ID: 15003652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006.
    Kinlin LM; Jamieson F; Brown EM; Brown S; Rawte P; Dolman S; Drews SJ; Fisman DN
    Vaccine; 2009 Mar; 27(11):1735-40. PubMed ID: 19186206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.